J A H Inkster1,2, S Zhang1,2, V Akurathi1,2, A Belanger3, S Dubey3, T Treves2,3, A B Packard1,2. 1. Boston Children's Hospital, Division of Nuclear Medicine and Molecular Imaging, Boston, MA, 02115, USA. 2. Harvard Medical School, Boston, MA 02115, USA. 3. Brigham & Women's Hospital, Boston, MA 02115, USA.
Abstract
New chemical and radiochemical syntheses are described for the preparation of [18F]Rho6G-DEG-F, an 18F-labeled analogue of the fluoresecent dye rhodamine 6G, which has shown promise as myocardidal perfusion imaging agent. Tosylated precursors of [18F]Rho6G-DEG-F amenable to 18F-labeling were obtained either through a two-step synthesis from rhodamine 6G lactone (33% yield), or in one step from rhodamine 575 (64% yield), then purified by preparative C18 chromatography. Manual synthesis of [18F]Rho6G-DEG-F was achieved in a single radiochemical step from either the tosylate salt or the tosylate/formate double salt in DMSO under standard nucleophillic aliphatic 18F-fluorination conditions (K[18F]F/K2CO3/Kryptofix 2.2.2.). Incorporation of the [18F]F- was found to be satisfactory (≥34% by TLC), despite the protic character of the precursor molecules. [18F]Rho6G-DEG-F was manually synthesized in final decay-corrected radiochemical yields of 11-26% (tosylate salt) and 9-21% (tosylate/formate double salt). The protocol was transferred to an automated synthesis unit, where the product was obtained in 3-9% radiochemical yield (n=3) decay corrected to start-of-synthesis, >99% radiochemical purity, and a molar activity of 122-267 GBq/μmol (3.3-7.2 Ci/μmol).
New chemical and radiochemical syntheses are described for the preparation of n class="Chemical">[18F]Rho6G-DEG-F, an 18F-labeled analogue of the fluoresecent dye rhodamine 6G, which has shown promise as myocardidal perfusion imaging agent. Tosylated precursors of [18F]Rho6G-DEG-F amenable to 18F-labeling were obtained either through a two-step synthesis from rhodamine 6G lactone (33% yield), or in one step from rhodamine 575 (64% yield), then purified by preparative C18 chromatography. Manual synthesis of [18F]Rho6G-DEG-F was achieved in a single radiochemical step from either the tosylate salt or the tosylate/formate double salt in DMSO under standard nucleophillic aliphatic 18F-fluorination conditions (K[18F]F/K2CO3/Kryptofix 2.2.2.). Incorporation of the [18F]F- was found to be satisfactory (≥34% by TLC), despite the protic character of the precursor molecules. [18F]Rho6G-DEG-F was manually synthesized in final decay-corrected radiochemical yields of 11-26% (tosylate salt) and 9-21% (tosylate/formate double salt). The protocol was transferred to an automated synthesis unit, where the product was obtained in 3-9% radiochemical yield (n=3) decay corrected to start-of-synthesis, >99% radiochemical purity, and a molar activity of 122-267 GBq/μmol (3.3-7.2 Ci/μmol).
Authors: Jamshid Maddahi; Johannes Czernin; Joel Lazewatsky; Sung-Cheng Huang; Magnus Dahlbom; Heinrich Schelbert; Richard Sparks; Alexander Ehlgen; Paul Crane; Qi Zhu; Marybeth Devine; Michael Phelps Journal: J Nucl Med Date: 2011-08-17 Impact factor: 10.057
Authors: Igal Madar; Hayden T Ravert; Yong Du; John Hilton; Lana Volokh; Robert F Dannals; James J Frost; Joshua M Hare Journal: J Nucl Med Date: 2006-08 Impact factor: 10.057
Authors: Mark D Bartholomä; Shaohui Zhang; Vamsidhar Akurathi; Christina A Pacak; Patricia Dunning; Frederic H Fahey; Douglas B Cowan; S Ted Treves; Alan B Packard Journal: Nucl Med Biol Date: 2015-06-18 Impact factor: 2.408
Authors: Mark D Bartholomä; Vijay Gottumukkala; Shaohui Zhang; Amanda Baker; Patricia Dunning; Frederic H Fahey; S Ted Treves; Alan B Packard Journal: J Med Chem Date: 2012-12-14 Impact factor: 7.446
Authors: Daniel S Berman; Jamshid Maddahi; B K Tamarappoo; Johannes Czernin; Raymond Taillefer; James E Udelson; C Michael Gibson; Marybeth Devine; Joel Lazewatsky; Gajanan Bhat; Dana Washburn Journal: J Am Coll Cardiol Date: 2012-12-19 Impact factor: 24.094
Authors: L Li; L Brichard; L Larsen; D K Menon; R A J Smith; M P Murphy; F I Aigbirhio Journal: J Labelled Comp Radiopharm Date: 2013-09-10 Impact factor: 1.921